Sugi Predict

Sugi Predict / Targets / EPAS1

EPAS1

Endothelial PAS domain-containing protein 1 · Q99814 · EPAS1 on Sugi Atlas →

49,457 patent compounds predicted against EPAS1, 26,708 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL507142 SCHEMBL507142 0.53 19/20
Achyrofuran Achyrofuran (SCHEMBL505137) 0.57 14/20
SCHEMBL587729 SCHEMBL587729 0.73 13/20
SCHEMBL260342 SCHEMBL260342 0.53 13/20
SCHEMBL508324 SCHEMBL508324 0.37 12/20
SCHEMBL286617 SCHEMBL286617 0.65 9/20
SCHEMBL218100 SCHEMBL218100 0.53 9/20
SCHEMBL86464 SCHEMBL86464 0.51 9/20
SCHEMBL291121 SCHEMBL291121 0.49 9/20
SCHEMBL12329 SCHEMBL12329 0.47 9/20
SCHEMBL290849 SCHEMBL290849 0.47 9/20
SCHEMBL329419 SCHEMBL329419 0.47 9/20
SCHEMBL329569 SCHEMBL329569 0.47 9/20
SCHEMBL446289 SCHEMBL446289 0.47 9/20
SCHEMBL223777 SCHEMBL223777 0.43 9/20
SCHEMBL419275 SCHEMBL419275 0.66 8/20
SCHEMBL526363 SCHEMBL526363 0.55 8/20
SCHEMBL482234 SCHEMBL482234 0.46 8/20
SCHEMBL263707 SCHEMBL263707 0.44 8/20
SCHEMBL91977 SCHEMBL91977 0.42 8/20

Clinical trials — most relevant to EPAS1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
Effect of Oral Supplementation With Curcumin (Turmeric) in Patients With Proteinuric Chronic Kidney Disease PHASE3COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy PHASE2NOT_YET_RECRUITING
Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag PHASE1/PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT PHASE2COMPLETED
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial) PHASE2RECRUITING
Study of the Effects of Iron on Lung Blood Pressure at High Altitude PHASE2WITHDRAWN
Spironolactone for Pulmonary Arterial Hypertension PHASE2RECRUITING
Digoxin for Congenital Erythrocytosis Due to Up-Regulated Hypoxia Sensing PHASE1WITHDRAWN
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease EARLY_PHASE1RECRUITING
Effect of Post Covid-19 Hypoxia on Placenta of Normal Pregnant Women: A Possible Role of Hypoxia Inducible Factor-1α. nanUNKNOWN
Mild Intermittent Hypoxia and Its Multipronged Effect on Sleep Apnea nanRECRUITING
Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock nanCOMPLETED
Tecfidera Diffusion Tensor Imaging nanCOMPLETED
Remote Ischemic Postconditioning Increases HIF-1α Plasma Levels and Improves Cardiac Markers After Cardiac Surgery nanCOMPLETED
Canola Oil Multicentre Intervention Trial nanCOMPLETED
Genetic Markers of Coronary Heart Disease in Type 2 Diabetes nanCOMPLETED
Rheo-Erythrocrine Dysfunction as a Biomarker for RIC Treatment in Acute Ischemic Stroke nanCOMPLETED
Genes-in-Action - Hepcidin Regulation of Iron Supplementation nanCOMPLETED
Mitochondrial Function of Immune Cells in Sepsis nanCOMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
Vascular Endothelial Factor Gene Polymorphism in Preeclampsia nanCOMPLETED
Expression of Angiogenic Factors in Myocardial Tissue nanCOMPLETED
Study of the Effects of Iron Levels on the Lungs at High Altitude nanCOMPLETED
The PRE-OP ENERGY Trial nanUNKNOWN
Blood Flow Responses to an Oral Glucose Tolerance Test in Type 2 Diabetes nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a EPAS1 binder may also engage these)

ProteinNameSimilarity
P97481 — 1.000 P97481 →
Q9JHS1 — 1.000 Q9JHS1 →
Q9XTA5 — 0.996 Q9XTA5 →
Q61221 — 0.994 Q61221 →
Q9I8A9 — 0.994 Q9I8A9 →
Q8R4S7 — 0.994 Q8R4S7 →
Q0PGG7 — 0.993 Q0PGG7 →
HIF1A Hypoxia-inducible factor 1-alpha 0.993 landscape →
Q8R4S2 — 0.992 Q8R4S2 →
P30561 — 0.992 P30561 →
Q8R4S6 — 0.992 Q8R4S6 →
Q8R4S4 — 0.991 Q8R4S4 →
P41738 — 0.991 P41738 →
Q8QGQ8 — 0.991 Q8QGQ8 →
Q8R4S5 — 0.991 Q8R4S5 →
Q91YA9 — 0.991 Q91YA9 →
Q8CJE2 — 0.991 Q8CJE2 →
O35800 — 0.990 O35800 →
Q5R4T2 — 0.990 Q5R4T2 →
O70361 — 0.990 O70361 →
Q98SW2 — 0.989 Q98SW2 →
Q5SSZ5 — 0.989 Q5SSZ5 →
O88529 — 0.989 O88529 →
Q9YIB9 — 0.989 Q9YIB9 →
Q9Z301 — 0.989 Q9Z301 →
A0MLS5 — 0.989 A0MLS5 →
P41739 — 0.988 P41739 →
Q5HZN1 — 0.988 Q5HZN1 →
Q32NH9 — 0.988 Q32NH9 →
Q8K3T2 — 0.988 Q8K3T2 →